STOCK TITAN
  1. Home
  2. News
  3. PEN

Penumbra Inc - PEN STOCK NEWS

Welcome to our dedicated news page for Penumbra (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Penumbra's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Penumbra's position in the market.

News
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
Rhea-AI Summary
Penumbra, Inc. (NYSE: PEN) will host a conference call to discuss first quarter 2024 financial results on May 7, 2024. The call will be at 4:30 PM Eastern Time. Investors can access the call via phone or webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
earnings
-
News
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Penumbra, Inc. (PEN) reported strong financial results for Q4 and full year 2023, showing revenue growth of 28.7% and 25.0% respectively. The company's income from operations and net income also saw significant increases. Penumbra projects total revenue growth of 16% to 20% for 2024, with positive expectations for U.S. thrombectomy growth and gross margin expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.25%
Tags
earnings
-
News
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024
Rhea-AI Summary
Penumbra, Inc. (PEN) will host a conference call to discuss financial results for the fourth quarter and full year 2023 on February 22, 2024. The company will issue a press release with financial results after market close on the same day. The conference call can be accessed via phone or webcast, and the webcast will be available on the company's website for at least two weeks after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
earnings
News
Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare Conference
Rhea-AI Summary
Penumbra, Inc. (NYSE: PEN) to present at J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
-
News
First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism
Rhea-AI Summary
Penumbra, Inc. (PEN) announced the enrollment of the first patient in STORM-PE, a randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism. The trial aims to advance the understanding of the role of computer assisted vacuum thrombectomy (CAVT) in the management of acute PE and improve patient outcomes. Penumbra's Lightning Flash™ offers the only CAVT technologies currently available in the U.S., with the latest advancement designed to remove large blood clots safely, simply, and with speed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
none
-
News
Penumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Penumbra, Inc. (PEN) to Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. The webcast of the presentation can be accessed on the company's website for at least two weeks following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
conferences
News
Penumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging Veterans
Rhea-AI Summary
Penumbra, Inc. (PEN) - Virtual Reality Companies Launch 'Honor Everywhere' Program for Aging Veterans. The press release discusses the 'Honor Everywhere' program, a collaboration between virtual reality companies and Honor Flight to provide immersive virtual reality experiences to aging and terminally ill Veterans who are unable to visit war memorials in person. The program aims to ensure that these Veterans can still commemorate their service and honor their fallen comrades through virtual tours. The initiative involves various VR companies, including Penumbra, Inc., contributing content to the immersive video collective, allowing Veterans to experience the memorials from the comfort of their homes. The program is available for download as an app on most virtual reality and mobile IOS and Android stores.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Penumbra, Inc. Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Penumbra, Inc. reports Q3 2023 financial results with revenue of $270.9 million, a 26.8% increase compared to Q3 2022. Sales of thrombectomy products increased by 38.0% to $179.1 million. Income from operations was $12.6 million, and net income was $9.2 million. Cash and marketable investments increased by $27.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
earnings
-
News
NEW LATE BREAKING DATA DEMONSTRATE PENUMBRA'S COMPUTER ASSISTED VACUUM THROMBECTOMY TECHNOLOGY FOR PULMONARY EMBOLISM IMPROVED PATIENT OUTCOMES
Rhea-AI Summary
Penumbra's computer assisted vacuum thrombectomy (CAVT) is safe and effective at reducing right heart strain and improving clinical and functional outcomes for the treatment of pulmonary embolism. The latest STRIKE-PE data show low rates of major adverse events and major bleeding. Functional measures also improved, including patient-reported shortness of breath, functional ability measured by 6-minute walk distance, and return to pre-PE state. The data confirm the significant benefits of CAVT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
none
News
Penumbra, Inc. Schedules Third Quarter 2023 Earnings Release and Conference Call for November 2, 2023
Rhea-AI Summary
Penumbra, Inc. to host conference call for Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
earnings
Stock PEN logo
Penumbra Inc

NYSE:PEN

PEN Rankings

#1104 Ranked by Market Cap
#1162 Ranked by Stock Gains
N/A Ranked by Dividends

PEN Stock Data

8.42B
37.19M
3.82%
89.81%
4.98%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Alameda

About PEN

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.